Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P3ZF
|
|||
| Drug Name |
IGF-MTX
|
|||
| Indication | Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.7; ICD-9: 205.1] | Phase 1/2 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1/2 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [2] | ||
| Company |
IGF OncologySt. Paul, MN
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02045368) Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.